Skip to main content

GINKGO BIOWORKS SHAREHOLDER NOTICE


Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their Options

 

NEW YORK, NY - (NewMediaWire) - October 29, 2021 - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. (“Ginkgo Bioworks” or the “Company”) (NYSE: DNA).

 

If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: http://www.faruqilaw.com/DNA.

A person in a suit

Description automatically generated with medium confidence

 

There is no cost or obligation to you. 

 

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.


On October 6, 2021, Scorpion Capital published a report about Ginkgo alleging that it is a "colossal scam." It describes the Company's business model as a "shell game," and that the company is highly dependent on related party transaction revenues. The report also calls the company a "Frankenstein mash-up of the worst frauds of the last 20 years."

 

On this news, the Company’s share price fell as much as 20%, during intraday trading on October 6, 2021, thereby injuring investors.


Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.